Back to CVE records
Medium 4.3Published Sep 26, 2026

CVE-2026-100525OpenClaw diagnostics-prometheus before 2026.9.3 Authentication Bypass

Updated under an hour ago ()

Does this affect you?

It affects openclaw diagnostics-prometheus. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

The OpenClaw Prometheus diagnostics plugin (@openclaw/diagnostics-prometheus) before version 2026.9.3 does not enforce the operator.read scope on its authenticated metrics endpoint. In deployments using an identity-bearing Gateway authentication mode such as trusted-proxy, a caller whose effective role has no read scope can retrieve the diagnostics document even though ordinary read methods reject the same identity, disclosing operational metrics to an authenticated profile intentionally limited below read access. Shared-secret Gateway callers already hold the documented full operator scope and are not affected. The issue is fixed in 2026.9.3; as a workaround, disable the Prometheus endpoint or ensure every identity that can reach it is intended to hold operator.read.

CVSS
4.3 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Weakness (CWE)
CWE-862
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulnCheck
NVD analysis
Deferred
Record last updated
Oct 8, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
openclaw diagnostics-prometheus
openclaw:diagnostics_prometheus (from the name)
before 2026.9.3; 2026.9.3 not affected
CNA record

References

  • vendor-advisory
  • third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.